Steris Plc Dossier
Qualitative Analysis
Business overview
STERIS plc (NYSE: STE) is a leading global provider of products and services focused on patient care, infection prevention, and sterilization. Legally registered in Dublin, Ireland, with operational headquarters in Mentor, Ohio, the company serves healthcare, pharmaceutical, and medical device customers worldwide. Following the divestment of its dental business, STERIS operates through three primary segments: Healthcare (providing sterilizers, surgical equipment, and reprocessing services), Applied Sterilization Technologies (AST, offering contract sterilization services for medical device manufacturers), and Life Sciences (delivering decontamination equipment and consumables for biopharma production).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Consolidating existing U.S. production into a state-of-the-art center of excellence in Mentor, Ohio.
Expected impact: Consolidates production to support long-term customer demand, drive compliance, and optimize manufacturing workflows.
Kicking off a multi-year project to upgrade service workflows with advanced technologies utilizing artificial intelligence (AI).
Expected impact: Aims to improve quality, increase productivity, and enhance the customer experience within both the Healthcare and Life Sciences segments.
Expanding outsourced sterilization network capacity, particularly focusing on completing the multi-year X-ray and E-beam expansion globally.
Expected impact: Captures outsourced sterilization demand driven by medical device OEMs exiting in-house processing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a family of GI products to expand the Healthcare segment's product offering and channel reach.
Financial impact: Combined with another tuck-in acquisition, it is expected to contribute approximately $45 million in revenue to fiscal 2027.
Tuck-in acquisition completed in the fourth quarter of fiscal 2026 to add to STERIS's global healthcare portfolio.
Financial impact: Combined with the GI products acquisition, it is expected to contribute approximately $45 million in revenue to fiscal 2027.
Strategic Partnerships
Blends STERIS's surgical and sterilization technologies with Fibonacci's regional installation, logistics, and technical support to modernize CSSD workflows in Latin America and the Caribbean [2.3.5].
Terms: Not publicly disclosed